http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2025, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 20 Feb 2025 18:15:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Aspire+Biopharma+Holdings%2C+Inc.+Announces+the+Execution+of+Securities+Purchase+Agreement/24381284.html <p><strong>NEW YORK CITY, NY / </strong><a href="https://www.accessnewswire.com/" rel="nofollow"><strong>ACCESS Newswire</strong></a><strong> / February 20, 2025 / </strong>Aspire Biopharma, Inc. ("Aspire" or the "Company"), a developer of a multi-faceted patent-protected disruptive drug delivery mechanism technology (Nasdaq:ASBP)(Nasdaq:ASBPW), today announced that it entered into a definitive Securities Purchase Agreement (the "Agreement") on February 19, 2025, pursuant to which the Company issued to the Buyers a senior secured convertible debenture (the "Debenture"). The Debenture is only convertible in the event of a default or at the Company's discretion. The closing of the transaction is expected to occur on February 20, http://www.streetinsider.com/Press+Releases/Aspire+Biopharma+Holdings%2C+Inc.+Announces+the+Execution+of+Securities+Purchase+Agreement/24381284.html Thu, 20 Feb 2025 18:15:00 -0500 ASBP ASBPW http://www.streetinsider.com/Accesswire/Aspire+Biopharma+Holdings%2C+Inc.+Announces+the+Execution+of+Securities+Purchase+Agreement/24381284.html <p><strong>NEW YORK CITY, NY / </strong><a href="https://www.accessnewswire.com/" rel="nofollow"><strong>ACCESS Newswire</strong></a><strong> / February 20, 2025 / </strong>Aspire Biopharma, Inc. ("Aspire" or the "Company"), a developer of a multi-faceted patent-protected disruptive drug delivery mechanism technology (Nasdaq:ASBP)(Nasdaq:ASBPW), today announced that it entered into a definitive Securities Purchase Agreement (the "Agreement") on February 19, 2025, pursuant to which the Company issued to the Buyers a senior secured convertible debenture (the "Debenture"). The Debenture is only convertible in the event of a default or at the Company's discretion. The closing of the transaction is expected to occur on February 20, http://www.streetinsider.com/Accesswire/Aspire+Biopharma+Holdings%2C+Inc.+Announces+the+Execution+of+Securities+Purchase+Agreement/24381284.html Thu, 20 Feb 2025 18:15:00 -0500 ASBP ASBPW http://www.streetinsider.com/Press+Releases/Aspire+Biopharma+Holdings%2C+Inc.+Announces+the+Execution+of+Securities+Purchase+Agreement/24381284.html <p><strong>NEW YORK CITY, NY / </strong><a href="https://www.accessnewswire.com/" rel="nofollow"><strong>ACCESS Newswire</strong></a><strong> / February 20, 2025 / </strong>Aspire Biopharma, Inc. ("Aspire" or the "Company"), a developer of a multi-faceted patent-protected disruptive drug delivery mechanism technology (Nasdaq:ASBP)(Nasdaq:ASBPW), today announced that it entered into a definitive Securities Purchase Agreement (the "Agreement") on February 19, 2025, pursuant to which the Company issued to the Buyers a senior secured convertible debenture (the "Debenture"). The Debenture is only convertible in the event of a default or at the Company's discretion. The closing of the transaction is expected to occur on February 20, http://www.streetinsider.com/Press+Releases/Aspire+Biopharma+Holdings%2C+Inc.+Announces+the+Execution+of+Securities+Purchase+Agreement/24381284.html Thu, 20 Feb 2025 18:15:00 -0500 ASBP ASBPW http://www.streetinsider.com/Accesswire/Aspire+Biopharma+Holdings%2C+Inc.+Announces+the+Execution+of+Securities+Purchase+Agreement/24381284.html <p><strong>NEW YORK CITY, NY / </strong><a href="https://www.accessnewswire.com/" rel="nofollow"><strong>ACCESS Newswire</strong></a><strong> / February 20, 2025 / </strong>Aspire Biopharma, Inc. ("Aspire" or the "Company"), a developer of a multi-faceted patent-protected disruptive drug delivery mechanism technology (Nasdaq:ASBP)(Nasdaq:ASBPW), today announced that it entered into a definitive Securities Purchase Agreement (the "Agreement") on February 19, 2025, pursuant to which the Company issued to the Buyers a senior secured convertible debenture (the "Debenture"). The Debenture is only convertible in the event of a default or at the Company's discretion. The closing of the transaction is expected to occur on February 20, http://www.streetinsider.com/Accesswire/Aspire+Biopharma+Holdings%2C+Inc.+Announces+the+Execution+of+Securities+Purchase+Agreement/24381284.html Thu, 20 Feb 2025 18:15:00 -0500 ASBP ASBPW